Hyperthermic isolated limb perfusion with tumor necrosis factor α, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: A multicenter study

Archives of Surgery

Volumn 134, Issue 3, 1999, Pages 303-307

  Olieman, Annette F T ^a   Liénard, Danielle ^d   Eggermont, Alexander M M ^b   Kroon, Bin B R ^c   Lejeune, Ferdy J ^d   Hoekstra, Harald J ^a   Koops, Heimen Schraffordt ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARM; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; HUMAN; LEG; LIMB PERFUSION; LIMB SALVAGE; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; METASTASIS; PRIORITY JOURNAL; REGIONAL PERFUSION; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA;

EID: 0345471470     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.134.3.303     Document Type: Article

References (27)

1. Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-632.
2. Baas PC, Schraffordt Koops H, Hoekstra HJ, Oosterhuis JW, van der Weele LT, Oldhoff J. Isolated regional perfusion in the treatment of local recurrence, satellitosis and in transit metastasis of the extremities. Reg Cancer Treat. 1988;1: 33-36.
3. Franklin HR, Schraffordt Koops H, Oldhoff J, et al. To perfuse or not to perfuse? a retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol. 1988;6:701-708.
4. Stehlin JS Jr. Hyperthermic perfusion with chemotherapy for cancer of the extremities. Surg Gynecol Obstet. 1969;129:305-308
5. Thompson JF, Giatoutsos MP. Isolated perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg. 1992;61:227-233.
6. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, et al. A combination of intraarterial chemotherapy, preoperative and postoperative radiotherapy, and surgery as limb saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. Cancer. 1989;63:59-62.
7. Klaase JM, Kroon BBR, Benckhuijsen C, Van Geel AN, Albus-Lutter ChE, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer. 1989;64:616-621.
8. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumour necrosis factor-alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
9. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α - in combination with interferon-γ - and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14:2653-2665.
10. Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129-1137.
11. Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis J. Isolated regional perfusion in malignant melanoma of the extremities. World J Surg. 1987;11: 527-533.
12. Olieman AFT, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-α. IFN-γ and melphalan for limb saving treatment in locally advanced extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1998;40:807-814.
13. Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: technique and results. Reg Cancer Treat. 1992;4:301-304.
14. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg. 1993;80:1124-1126.
15. Hoekstra HJ, Schraffordt Koops H, Oldhoff J. Soft tissue sarcoma of the extremity. Eur J Surg Oncol. 1994;20:3-6.
16. Mazanet R, Antman KH. Sarcomas of soft tissue and bone. Cancer. 1991;68: 463-473.
17. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci U S A. 1975;72:3666-3670
18. Renard N, Lienard D, Lespagnard L, Eggermont A, Heiman R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer. 1994;57:656-663.
19. Pan M, Wasa M, Lind S, Gertler J, Abbott W, Suoba W. TNF-stimulated arginine transport by human endothelium requires activation of protein kinase C. Ann Surg. 1995;221:590-601.
20. Eggermont AMM, Lienard D, Schraffordt Koops H, Rosenkaimer F, Lejeune FJ. Treatment of irresectable soft-tissue sarcomas of the limbs by isolation perfusion with high-dose TNFα in combination with interferon-γ and melphalan. In: Fiers W, Buurman W. eds. Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Farmington, Conn: S Karger AG: 1993:239-243.
21. Olieman AFT, van Ginkel RJ, Hoekstra HJ, et al. The angiographic response of locally advanced soft tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol. 1997;4:64-69.
22. Lienard D, Eggermont AMM, Schrafford Koops H, et al. Isolated perfusion of the limb with high-dose TNFα, IFNγ and melphalan for melanoma stage III: results of a multicentric pilot study. Melanoma Res. 1994;4:21-26.
23. Eggermont AMM, Schraffordt Koops H, Klausner J, et al. Isolated limb perfusion with tumour necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg. 1996;224:756-765.
24. Olieman AFT, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Hyperthermic isolated limb perfusion with TNF-α and melphalan as palliative limb-saving treatment in patients with locally advanced soft tissue sarcomas of the extremities with regional or distant metastases: is it worthwhile? Arch Orthop Trauma Surg 1998;118:70-74.
25. Robinson JK. What are adequate treatment and follow-up care for nonmelanoma cutaneous cancer? Arch Dermatol. 1987;123:331-333.
26. Vaglini M, Andreola S, Attili A, et al. Limb-salvage procedure in two patients with spindle cell carcinoma of the lower extremities using isolation perfusion. Tumori. 1985;71:271-275.
27. Fenig E, Brenner B, Katz A, Rakovsky E, Hana MB, Sulkes A. The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer. 1997;80:881-885.